InvivoSciences, Inc. (IVS), founded in Madison, United States, is a precision medicine company focused on personalizing drug development. Their core mission is to revolutionize drug discovery and repositioning by utilizing patient-derived and gene-edited human samples. IVS offers phenotypic compound screening services, leveraging an automated, scalable platform that includes functional 3D engineered micro-human heart tissue. Their market focus is on providing innovative solutions for first-in-class drug discovery and drug repositioning.
Notable affiliated people and investors include experts in computational biology and tissue engineering, though specific names are not disclosed. Key achievements of IVS include the development of their unique 3D micro-tissue platform and integration of AI for tissue phenotyping assays. The overall impact of InvivoSciences has been significant in advancing precision medicine, offering more personalized and effective treatments through cutting-edge technology in drug development.
